Financial Associated Press, on October 23rd (Reporter He Fan) Is the 'Maotai Liquor for women' losing its appeal? From the third quarter report released this evening, imeik technology development (300896.SZ) has shown some growth in performance, but the growth rates of Q3 company revenue and net income attributable to shareholders have slowed down to 1% and 2% respectively. Seeking new growth opportunities, imeik technology development's research and development expenses continue to increase, with a presence in areas like weight management drugs and botulinum toxin.

Tonight, imeik technology development released the third quarter report for 2024. The company achieved revenue of 2.376 billion yuan in the first three quarters, an increase of 9.46% year-on-year; net income attributable to shareholders was 1.586 billion yuan, an increase of 11.79% year-on-year. In Q3, revenue reached 0.719 billion yuan, an increase of 1.10% year-on-year, and net income attributable to shareholders was 0.465 billion yuan, an increase of 2.13% year-on-year. Compared to Q2, total revenue in Q3 decreased by 0.13 billion yuan, and net income attributable to shareholders decreased by 0.128 billion yuan.

On the other hand, to cope with the crowded medical beauty market and find new growth opportunities, imeik technology development's research and development expenses continue to increase, with R&D expenses in the first three quarters of this year increasing to 0.187 billion yuan, a 17.61% increase compared to the same period last year.

Recently, imeik technology development has made progress in new products and research progress. On October 9th, the 'Medical device registration certificate' for the 'cross-linked hyaluronic acid sodium gel containing polyethylene glycol microspheres for subcutaneous injection in the upper layer of adult dermis to improve mild to moderate chin retractions' was issued by the National Medical Products Administration. On the 14th of this month, imeik technology development announced that its wholly-owned subsidiary Nuo Bot Bio received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration regarding the siomeglumide injection solution, and will conduct clinical trials soon.

However, the competition in the medical aesthetics market may be more intense than expected. On July 3rd, imeik technology development announced that its registration application for Type A botulinum toxin for injection was accepted. However, on September 9th, Fosun Pharma announced that its Type A botulinum toxin for injection had been approved, becoming the sixth approved botulinum toxin in the country. Then, on September 13th, Huadong Medicine stated on its official WeChat account that in a strategic partnership with Yuyan Pharmaceuticals, the Phase III clinical study of the strategic collaboration product YY001, a recombinant Type A botulinum toxin for injection, for the treatment of moderate to severe glabellar lines, has been completed.